WHAT IS CLAIMED IS:

1. A method for prophylaxis or treatment of breast cancer in a mammalian patient comprising administering to said patient a therapeutically effective amount of one or more compound(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier sufficient to inhibit initiation or growth of breast cancer in said patient.

2. The method of claim 1, wherein said one or more oxytocin analogue(s) comprises carbetocin.

3. The method of claim 1, wherein said one or more oxytocin analogue(s) is/are administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery.

4. The method of claim 3, wherein said one or more oxytocin analogue(s) is/are administered to said patient intranasally.

5. The method of claim 3, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.

6. The method of claim 5, wherein said one or more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.

7. The method of claim 6, wherein said one or more oxytocin analogue(s) is/are combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

8. The method of claim 6, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.

9. The method of claim 1, wherein said one or more oxytocin analogue(s) is/are administered in a dose of at least one microgram.

10 The method of claim 1, wherein said one or more oxytocin analogue(s) is/are administered daily in an intranasal formulation.

11. The method of claim 1, further comprising administering tamoxifen and/or raloxifene to said patient in an amount sufficient to inhibit initiation or growth of estrogen-dependent breast cancer in said patient.

12. The method of claim 11, wherein said one or more oxytocin analogue(s) and said tamoxifen and/or raloxifene are administered simultaneously as a mixture.

13. A method for prophylaxis or treatment of a psychiatric disorder in a mammalian patient comprising administering to said patient a therapeutically effective amount of one or more compound(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier sufficient to alleviate an obsessive-compulsive behavior of said disorder in said patient.

14. The method of claim 13, wherein said psychiatric disorder is obsessive compulsive disorder, Praeder Willi syndrome or autism.

15. The method of claim 13, wherein said one or more oxytocin analogue(s) comprises carbetocin.

16. The method of claim 13, wherein said one or more oxytocin analogue(s) is/are administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, and transdermal delivery.

17. The method of claim 16, wherein said one or more oxytocin analogue(s) is/are administered to said patient intranasally.

18. The method of claim 16, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.

19. The method of claim 18, wherein said one or more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.

20. The method of claim 19, wherein said one or more oxytocin analogue(s) is/are combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

21. The method of claim 19, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.

22. The method of claim 13, wherein said one or more oxytocin analogue(s) is/are administered in a dose of at least one microgram.

23 The method of claim 13, wherein said one or more oxytocin analogue(s) is/are administered daily in an intranasal formulation.

24. The method of claim 13, further comprising administering a selective serotonin reuptake inhibitor or serotonin reuptake inhibitor to said patient in an amount sufficient to alleviate an obsessive-compulsive behavior in said patient.

25. The method of claim 24, wherein said one or more oxytocin analogue(s) and said selective serotonin reuptake inhibitor are administered simultaneously as a mixture.

26. A pharmaceutical composition for prophylaxis or treatment of breast cancer in a mammalian patient comprising a therapeutically effective amount of one or more oxytocin analogue(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier, wherein said composition is sufficient to inhibit initiation or growth of breast cancer in said patient.

27. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) comprises carbetocin.

28. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.

29. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.

30. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) is/are combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.

31. The pharmaceutical composition of claim 26, prepared in a unit dosage form containing at least one microgram of said one or more oxytocin analogue(s).

32. The pharmaceutical composition of claim 26, further comprising tamoxifen and/or raloxifen in an amount sufficient to inhibit initiation or growth of estrogen-dependent breast cancer in said patient.

33. A medicament suspension or powder for nasal administration to treat or prevent breast cancer comprising carbetocin and a powder of one or more cation exchange resins and/or one or more adsorbent resins.

34. A pharmaceutical composition for prophylaxis or treatment of a psychiatric disorder in a mammalian patient comprising a therapeutically effective amount of one or more oxytocin analogue(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier, wherein said composition is sufficient to alleviate at least one symptom of said psychiatric disorder in said patient.

35. The pharmaceutical composition of claim 34, wherein said one or more oxytocin analogue(s) comprises carbetocin.

36. The pharmaceutical composition of claim 34, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.

37. The pharmaceutical composition of claim 34, wherein said one or more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.

38. The pharmaceutical composition of claim 34, further comprising a selective serotonin reuptake inhibitor or serotonin reuptake inhibitor.